Johnson & Johnson increased its guidance for its full-year sales performance after notching 27% sales growth across all divisions year over year, according to its earnings report released Wednesday.
The New Brunswick, N.J.–based company reported $23.3 billion in sales during the second quarter due to market recovery and surging demand for medical devices, drugs and consumer-health products. Adjusted earnings were $2.48 per share, an increase of 48.5% year over year.
Its net income jumped 73%, to nearly $6.3 billion from $3.6 billion, in the second quarter of 2020, the company said.
Pharmaceuticals, including its one-shot Covid-19 vaccine, accounted for more than half its sales during the quarter,
→ Continue reading at Crain's New York Business